A new subsidiary to tackle depression

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

atai Life Sciences (ATAI) and Chymia LLC launched a new company to offer individualized care for patients with treatment-resistant depression (TRD).

The company, PsyProtix, takes a precision psychiatry approach – an emerging method that treats illnesses based on each patient’s genetic, metabolic, environmental, and lifestyle variability.

The platform should allow patients to be diagnosed and treated faster and more effectively than when following protocols designed for the majority.

PDF of article